(Q38439266)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

review article

1 reference

title

Mechanisms of aromatase inhibitor resistance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Izabela Chmielewska

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Cynthia X Ma

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Matthew J Ellis

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

1 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

261-275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25907219%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc3920

6 March 2020

exact match

0 references

cites work

Advances in adjuvant endocrine therapy for postmenopausal women

1 reference

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

31 March 2020

1 reference

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

31 March 2020

1 reference

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

31 March 2020

1 reference

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

31 March 2020

1 reference

Overcoming endocrine therapy resistance by signal transduction inhibition

31 March 2020

1 reference

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

31 March 2020

1 reference

Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

31 March 2020

1 reference

Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters

31 March 2020

1 reference

Genome remodelling in a basal-like breast cancer metastasis and xenograft

31 March 2020

1 reference

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

31 March 2020

1 reference

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

31 March 2020

1 reference

Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer

31 March 2020

1 reference

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

31 March 2020

1 reference

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

31 March 2020

1 reference

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

31 March 2020

1 reference

Whole-genome analysis informs breast cancer response to aromatase inhibition

31 March 2020

1 reference

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

31 March 2020

1 reference

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

31 March 2020

1 reference

Comprehensive molecular portraits of human breast tumours

31 March 2020

1 reference

Molecular pathways: extracting medical knowledge from high-throughput genomic data

31 March 2020

1 reference

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer

31 March 2020

1 reference

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers

31 March 2020

1 reference

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer

31 March 2020

1 reference

RNA-Seq mapping and detection of gene fusions with a suffix array algorithm

31 March 2020

1 reference

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

31 March 2020

1 reference

Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer

31 March 2020

1 reference

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

31 March 2020

1 reference

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

31 March 2020

1 reference

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer

31 March 2020

1 reference

Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues reveals a link to tumor progression.

31 March 2020

1 reference

Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells

31 March 2020

1 reference

Targeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis

31 March 2020

1 reference

Absence of ESR1 amplification in a series of breast cancers

31 March 2020

1 reference

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

31 March 2020

1 reference

ESR1 gene amplification in breast cancer: a common phenomenon?

31 March 2020

1 reference

ESR1 gene amplification in breast cancer: a common phenomenon?

31 March 2020

1 reference

ESR1 gene amplification in breast cancer: a common phenomenon?

31 March 2020

1 reference

ESR1 gene amplification in breast cancer: a common phenomenon?

31 March 2020

1 reference

Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study

31 March 2020

1 reference

ESR1 amplification in breast cancer: controversy resolved?

31 March 2020

1 reference

On the evidence for ESR1 amplification in breast cancer

31 March 2020

1 reference

Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.

31 March 2020

1 reference

ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study.

31 March 2020

1 reference

ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous

31 March 2020

1 reference

Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer

31 March 2020

1 reference

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

31 March 2020

1 reference

Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer

31 March 2020

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

31 March 2020

1 reference

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

31 March 2020

1 reference

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

31 March 2020

1 reference

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

31 March 2020

1 reference

Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells

31 March 2020

1 reference

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

31 March 2020

1 reference

Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells

31 March 2020

1 reference

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

31 March 2020

1 reference

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

31 March 2020

1 reference

Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies

31 March 2020

1 reference

The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm

31 March 2020

1 reference

Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors

31 March 2020

1 reference

Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

31 March 2020

1 reference

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

31 March 2020

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells

31 March 2020

1 reference

The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane

31 March 2020

1 reference

Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

31 March 2020

1 reference

Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1

31 March 2020

1 reference

Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer

31 March 2020

1 reference

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

31 March 2020

1 reference

Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1

31 March 2020

1 reference

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

31 March 2020

1 reference

Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance

31 March 2020

1 reference

AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.

31 March 2020

1 reference

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

31 March 2020

1 reference

Plasma membrane estrogen receptors

31 March 2020

1 reference

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

31 March 2020

1 reference

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

31 March 2020

1 reference

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

31 March 2020

1 reference

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal

31 March 2020

1 reference

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

31 March 2020

1 reference

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

31 March 2020

1 reference

Activating HER2 mutations in HER2 gene amplification negative breast cancer

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

31 March 2020

1 reference

PIK3CA mutation associates with improved outcome in breast cancer.

31 March 2020

1 reference

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

31 March 2020

1 reference

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

31 March 2020

1 reference

Dynamic FoxO transcription factors

31 March 2020

1 reference

Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway

31 March 2020

1 reference

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

31 March 2020

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

31 March 2020

1 reference

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

31 March 2020

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

31 March 2020

1 reference

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

31 March 2020

1 reference

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

31 March 2020

1 reference

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

31 March 2020

1 reference

Targeting the MDM2-p53 interaction for cancer therapy

31 March 2020

1 reference

Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer

31 March 2020

1 reference

Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.

31 March 2020

1 reference

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole

31 March 2020

1 reference

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

31 March 2020

1 reference

Scriptaid effects on breast cancer cell lines

31 March 2020

1 reference

Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells

31 March 2020

1 reference

Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance

31 March 2020

1 reference

Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A.

31 March 2020

1 reference

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

31 March 2020

1 reference

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

31 March 2020

1 reference

Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis

31 March 2020

1 reference

GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells

31 March 2020

1 reference

Targeting apoptosis pathways in cancer stem cells

31 March 2020

1 reference

Death receptor agonists as a targeted therapy for cancer

31 March 2020

1 reference

Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells.

31 March 2020

1 reference

Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner.

31 March 2020

1 reference

Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies

31 March 2020

1 reference

MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.

31 March 2020

1 reference

Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar

31 March 2020

1 reference

Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists

31 March 2020

1 reference

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.

31 March 2020

1 reference

Hedgehog signaling: networking to nurture a promalignant tumor microenvironment

31 March 2020

1 reference

Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling

31 March 2020

1 reference

Selective targeting of radiation-resistant tumor-initiating cells

31 March 2020

1 reference

Targeting breast cancer stem cells

31 March 2020

1 reference

Prospective identification of tumorigenic breast cancer cells

31 March 2020

1 reference

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

31 March 2020

1 reference

Highly sensitive profiling of CD44+/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway.

31 March 2020

1 reference

Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.

31 March 2020

1 reference

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

31 March 2020

1 reference

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch

31 March 2020

1 reference

The impact of tumor stroma on drug response in breast cancer

31 March 2020

1 reference

Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells.

31 March 2020

1 reference

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

31 March 2020

1 reference

Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

31 March 2020

1 reference

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer

31 March 2020

1 reference

Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features

31 March 2020

1 reference

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.

31 March 2020

1 reference

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

31 March 2020

1 reference

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells

31 March 2020

1 reference

Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells

31 March 2020

1 reference

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

31 March 2020

1 reference

Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence.

31 March 2020

1 reference

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling

31 March 2020

1 reference

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages

31 March 2020

1 reference

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling

31 March 2020

1 reference

Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells

31 March 2020

1 reference

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

31 March 2020

1 reference

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients

31 March 2020

1 reference

Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

31 March 2020

1 reference

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance

31 March 2020

1 reference

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

31 March 2020

1 reference

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

31 March 2020

1 reference

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

31 March 2020

1 reference

Targeting tumor-stromal interactions in bone metastasis

31 March 2020

1 reference

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

31 March 2020

1 reference

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

31 March 2020

1 reference

Cancer to bone: a fatal attraction

31 March 2020

1 reference

Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence

31 March 2020

1 reference

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis

31 March 2020

1 reference

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

31 March 2020

1 reference

Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells

31 March 2020

1 reference

12 December 2020

Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition

1 reference

12 December 2020

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

1 reference

12 December 2020

Variant human breast tumor estrogen receptor with constitutive transcriptional activity

1 reference

12 December 2020

Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations

1 reference

12 December 2020

Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm

1 reference

12 December 2020

An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer

1 reference

12 December 2020

The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).

1 reference

12 December 2020

Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells

1 reference

12 December 2020

Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

1 reference

12 December 2020